BiotechTube

6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine alone

Phase 3Recruiting
2 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Carcinoma, Non-Small -Cell Lung

Conditions

Carcinoma, Non-Small -Cell Lung

Trial Timeline

Dec 8, 2025 → Dec 31, 2027

NCT ID
NCT06908304

About 6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine alone

6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine alone is a phase 3 stage product being developed by MAIA Biotechnology for Carcinoma, Non-Small -Cell Lung. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06908304. Target conditions include Carcinoma, Non-Small -Cell Lung.

What happened to similar drugs?

20 of 20 similar drugs in Carcinoma, Non-Small -Cell Lung were approved

Approved (20) Terminated (1) Active (0)
✅Enfortumab VedotinAstellas PharmaApproved
✅Sonidegib Phosphate CapsulesSun PharmaceuticalApproved
✅LenvatinibEisaiApproved
✅Epirubicin + lipiodolJohnson & JohnsonApproved
✅ApatinibTabletsJiangsu Hengrui MedicineApproved
✅Gefitinib + DocetaxelAstraZenecaApproved
✅Olaparib + BevacizumabAstraZenecaApproved

Hype Score Breakdown

Clinical
17
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06908304Phase 3Recruiting

Competing Products

20 competing products in Carcinoma, Non-Small -Cell Lung

See all competitors
ProductCompanyStageHype Score
CD40 agonist mitazalimab in combination with chemotherapyAlligator Bioscience ABPhase 1/2
26
AFM24 + SNK01AffimedPhase 1/2
14
NRC-2694-A + PaclitaxelNatco PharmaPhase 2
42
Sintilimab + Nab paclitaxel + CisplatinCSPC Pharmaceutical Group LimitedPhase 2
35
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + BendamustineLonzaPhase 1
18
Pemetrexed + CarboplatinEli LillyPhase 3
40
PRGN-3005 UltraCAR-T cells + PRGN-3005 UltraCAR-T cellsPrecigenPhase 1
27
Cemiplimab + CetuximabEli LillyPhase 2
42
IMC-1121B (ramucirumab) + Oxaliplatin + Folinic acid + 5-FU + 5-FUEli LillyPhase 2
35
[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359Perspective TherapeuticsPhase 1/2
33
CT-01 + EVEROLIMUSCaptor TherapeuticsPhase 1
26
BB-401Benitec BiopharmaPhase 2
25
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
29
AzenosertibZentalis PharmaceuticalsPhase 2
25
6-Thio-2'-Deoxyguanosine + CemiplimabMAIA BiotechnologyPhase 2
32
ateganosine + CadonilimabMAIA BiotechnologyPhase 1
26
gemcitabine + carboplatin + cisplatinEli LillyPhase 2
35
CetuximabEli LillyPhase 1
29
Ramucirumab + PaclitaxelEli LillyPhase 2
35
LY2875358 + ErlotinibEli LillyPhase 2
35